share_log

Longevity Biomedical, Inc. And Denali Capital Acquisition Corp. Announce Business Combination

Longevity Biomedical, Inc. And Denali Capital Acquisition Corp. Announce Business Combination

长寿生物医学公司和德纳利资本收购公司宣布业务合并
Benzinga Real-time News ·  2023/01/26 06:35
  • Longevity Biomedical is focused on developing and acquiring new technologies spanning therapeutics, health monitoring and digital health solutions to become a leading provider of longevity-related products and services designed to increase health span for the rapidly growing global aging population.
  • Late-stage, diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair.
  • Total proceeds expected to bring minimum pro forma cash balance of $30 million with cash runway into 2025.
  • Near-term clinical milestones include Phase 3 start for LBI-201 for Ischemic stroke, Phase 2 data for LBI-101 for soft-tissue reconstruction, Phase 2 start for LBI-001 in retinal vein occlusion, and completion of preclinical and formulation studies for LBI-002 in corneal blindness.
  • Seasoned management team of medtech and biopharmaceutical veterans with track record of acquiring, developing and commercializing novel technologies.
  • Post-combination company to list on Nasdaq under ticker symbol "LBIO."
  • Business combination expected to close in Q2 2023.
  • 长寿生物医疗专注于开发和获取涵盖治疗、健康监测和数字健康解决方案的新技术，成为与长寿相关的产品和服务的领先提供商，旨在为快速增长的全球老龄化人口增加健康寿命。
  • 眼科、心血管疾病和软组织重建和修复的晚期、多样化的候选治疗流水线。
  • 预计总收益将使预计现金余额至少达到3000万美元，现金跑道将持续到2025年。
  • 近期的临床里程碑包括用于缺血性中风的LBI-201的第三阶段开始，用于软组织重建的LBI-101的第二阶段数据，用于视网膜静脉阻塞的LBI-001的第二阶段开始，以及用于角膜失明的LBI-002的临床前和配方研究的完成。
  • 经验丰富的医疗技术和生物制药资深管理团队，拥有获取、开发和商业化新技术的记录。
  • 合并后的公司将在纳斯达克上市，股票代码为“LBIO”。
  • 业务合并预计将于2023年第二季度完成。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发